Delayed-setting calcium phosphate pastes

• US 8,216,359 B2
• Filed: 04/14/2005
• Issued: 07/10/2012
• Est. Priority Date: 04/15/2004
• Status: Active Grant

• Current Assignee: Etex Corporation (Zimmer Biomet Holdings, Inc.)
• Original Assignee: Etex Corporation (Zimmer Biomet Holdings, Inc.)
• Inventors: Rosenberg, Aron D., Sutaria, Manish, Tofighi, Aliassghar N., Lee, Dosuk D., Gilles De Pelichy, Laurent D.
• Primary Examiner(s): Lorengo, Jerry
• Assistant Examiner(s): Barcena, Carlos
• Application Number:
  US11/578,337
• Publication Number:
  US 20080028992A1
• Time in Patent Office: 2,644 Days
• Field of Search: 424/601, 424/602, 424/57, 106/690, 106/691, 606/76, 606/77, 606/86.R, 606/92, 423/308
• US Class Current: 106/690
• CPC Class Codes: A61F 2/30767 Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
• CPC Class Codes: A61F 2310/00293 containing a phosphorus-containing compound, e.g. apatite
• CPC Class Codes: A61F 2310/00796 Coating or prosthesis-covering structure made of a phosphorus-containing compound, e.g. hydroxy(l)apatite
• CPC Class Codes: A61L 2300/256 Antibodies, e.g. immunoglobulins, vaccines
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 24/0015 Medicaments; Biocides
• CPC Class Codes: A61L 24/02 containing inorganic materials
• CPC Class Codes: A61L 27/12 Phosphorus-containing materials, e.g. apatite
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: G06Q 99/00 Subject matter not provided for in other groups of this subclass

Abstract

The invention features delayed-setting calcium phosphate pastes which are useful for the preparation of delivery vehicles for biologically active agents, useful for the treatment of orthopedic conditions and can be stored for long periods without prematurely setting.

Claims

1. A paste comprising a calcium phosphate material in an amount of at least 55% (w/w) and a non-aqueous liquid, in an amount of 5% to 20% (w/w), selected from dimethyl sulfoxide, N-methyl 2-pyrrolidone, glycofurol, ethyl lactate, ethanol, 1,2-dimethoxyethane, diglyme, dimethyl isosorbide, tetrahydrofurfuryl alcohol, triacetin, propylene carbonate, lecithin, and combinations thereof, wherein said paste comprises less than 5% (w/w) water and said paste forms a hardened poorly crystalline apatitic (PCA) calcium phosphate material when said non-aqueous liquid diffuses from said paste.

2. The paste of claim 1, said paste comprising less than 1% (w/w) water.

3. The paste of claim 2, said paste comprising at least 10% (w/w) of said non-aqueous liquid.

4. The paste of claim 1, wherein said calcium phosphate material is calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, tricalcium phosphate dihydrate, crystalline hydroxyapatite (HA), poorly crystalline calcium phosphate (PCA), calcium pyroposphate, monetite, octacalcium phosphate, amorphous calcium phosphate, or mixtures thereof.

5. The paste of claim 4, wherein said calcium phosphate material comprises a poorly crystalline calcium phosphate.

6. The paste of claim 4, wherein said calcium phosphate material comprises amorphous calcium phosphate.

7. The paste of claim 6, said paste comprising 20% (w/w) of said non-aqueous liquid, wherein said paste comprises less than 1% (w/w) water.

8. The paste of claim 1, wherein said liquid comprises N-methyl 2-pyrrolidone.

9. The paste of claim 1, further comprising a supplementary material.

10. The paste of claim 9, wherein said supplementary material comprises a bioerodible polymer selected from the group consisting of a polysaccharide, nucleic acid, carbohydrate, protein, polypeptide, poly(α

-hydroxy acid), poly(lactone), poly(amino acid), poly(anhydride), poly(orthoester), poly (anhydride-co-imide), poly(orthocarbonate), poly(α

-hydroxy alkanoate), poly(dioxanone), and poly(phosphoester), and mixtures thereof.

11. The paste of claim 10, wherein said supplementary material comprises a bioerodible material selected from the group consisting of collagen, glycogen, chitin, starch, keratins, silk, demineralized bone matrix, hyaluronic acid, poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide (PLGA), poly(L-lactide-co-D, L-lactide), poly(D,L-lactide-co-trimethylene carbonate), polyhydroxybutyrate (PHB), poly(ε

-caprolactone), poly(δ

-valerolactone), poly(γ

-butyrolactone), and poly(caprolactone), and mixtures thereof.

12. The paste of claim 9, wherein said supplementary material comprises a non-erodible material selected from the group consisting of dextran, cellulose, polyethylene, polymethylmethacrylate, carbon fiber, poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-polypropylene oxide) block copolymer, and poly(ethylene terephthalate)polyamide, and mixtures thereof.

13. The paste of claim 12, wherein said cellulose is methylcellulose, carboxy methylcellulose, hydroxypropyl methylcellulose, or hydroxyethyl cellulose.

14. The paste of claim 1, further comprising a biologically active agent.

15. The paste of claim 14, wherein said biologically active agent is an osteogenic protein, antibiotic, polynucleotide, anti-cancer agent, growth factor, or vaccine.

16. The paste of claim 15, wherein said osteogenic protein is BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, or BMP-18.

17. The paste of claim 14, wherein said biologically active agent is an alkylating agent, platinum agent, antimetabolite, topoisomerase inhibitor, antitumor antibiotic, antimitotic agent, aromatase inhibitor, thymidylate synthase inhibitor, DNA antagonist, farnesyltransferase inhibitor, pump inhibitor, histone acetyltransferase inhibitor, metalloproteinase inhibitor, ribonucleoside reductase inhibitor, TNF alpha agonist, TNF alpha antagonist, endothelin A receptor antagonist, retinoic acid receptor agonist, immuno-modulator, hormonal agent, antihormonal agent, photodynamic agent, or tyrosine kinase inhibitor.

18. The paste of claim 1, further comprising an effervescent agent.

19. The paste of claim 18, wherein said effervescent is sodium bicarbonate.

20. The paste of claim 19, wherein said paste is from about 1 to about 40 percent (w/w) sodium bicarbonate.

21. A kit comprising:

(i) the paste of claim 1, and

(ii) instructions for implanting said paste into a mammal.

22. The kit of claim 21, wherein said paste further comprises a biologically active agent.

27. A method of promoting bone growth at a site in need thereof, said method comprising applying to said site the paste of claim 1.

28. The method of claim 27, wherein said site is the surface of an orthopedic implant.

29. The method of claim 27, wherein said site is a bone fracture.

30. The method of claim 27, wherein said paste further comprises a biologically active agent.

31. A method of preparing a structural support for segmented bone, said method comprising contacting bone segments with the paste of claim 1.

32. The method of claim 31, further comprising contacting fixation hardware with said paste.

33. The method of claim 32, wherein said fixation hardware is selected form screws and plates.

23. A method of preparing an implant, comprising:

(i) preparing a paste comprising a calcium phosphate material in an amount of at least 55% (w/w) and a non-aqueous liquid in an amount of 5% to 20% (w/w), wherein said non-aqueous liquid is selected from dimethyl sulfoxide, N-methyl 2-pyrrolidone, glycofurol, ethyl lactate, ethanol, 1,2- dimethoxyethane, diglyme, dimethyl isosorbide, tetrahydrofurfuryl alcohol, triacetin, propylene carbonate, lecithin, and combinations thereof and wherein said paste comprises less than 5% (w/w) water, and

(ii) allowing said paste to form a hardened poorly crystalline apatitic (PCA) calcium phosphate material when said non-aqueous liquid diffuses from said paste.

24. The method of claim 23, wherein said paste further comprises a supplementary material.

25. The method of claim 23, wherein step (ii) occurs inside a mammal.

26. The method of claim 23, wherein said implant comprises a biologically active agent.